Epidermal growth factor receptor cancer-specific conformer (EGFR (conformer/variant))

The Epidermal Growth Factor Receptor (EGFR) cancer-specific conformer/variant refers to a distinct structural state of the EGFR protein that is selectively expressed or accessible on the surface of malignant cells, such as those in esophageal squamous cell carcinoma (ESCC). This target primarily encompasses the EGFRvIII (de2-7 EGFR) deletion mutant, which lacks a portion of the extracellular domain, and the 806 epitope, a cryptic sequence (residues 287–302) that is hidden in the normal tethered conformation of wild-type EGFR but becomes exposed when the receptor is overexpressed, mutated, or misfolded. Because this conformer is virtually absent on normal cells expressing physiological levels of wild-type EGFR, it provides a highly specific therapeutic window for targeted oncology treatments. In esophageal squamous cell carcinoma, the presence of this variant drives aggressive tumor growth and survival through the constitutive or hypersensitive activation of downstream signaling pathways, including PI3K/Akt and MAPK. Therapeutic strategies targeting this conformer include specialized monoclonal antibodies like mAb 806 and its humanized derivative depatuxizumab, as well as antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapies. These agents are designed to exploit the unique structural features of the cancer-associated receptor to deliver cytotoxic payloads or induce immune-mediated cell death while sparing healthy epithelial tissues that express only the wild-type, inactive conformation of EGFR.

Other names

EGFRvIIIde2-7 EGFR806-epitope EGFRDelta-EGFRType III EGFR mutationCancer-specific EGFREGFR variant III

Selective binding to a cryptic epitope (amino acids 287–302) exposed only in truncated (EGFRvIII) or overexpressed/activated conformations of EGFR, leading to inhibition of ligand-independent signaling and induction of antibody-dependent cellular cytotoxicity (ADCC) or delivery of cytotoxic payloads.